COUNTERFEIT ZANTAC SEIZURE INVOLVES 1,454 BOTTLES
Executive Summary
COUNTERFEIT ZANTAC SEIZURE INVOLVES 1,454 BOTTLES labeled as Glaxo's "Zantac 150." Each bottle contains 60 tabs. Following the filing of an April 12 complaint by Glaxo alleging that certain Zantac 150 tablets were counterfeit and liable to seizure, a U.S. marshall retrieved the bottles from FDA's New York district office. According to the complaint, which was filed in Brooklyn Federal Court, FDA originally seized the product, on July 21, from World Medical and Surgical Supply Corp. of Flushing, New York, and from E.M. Sales, Inc. of Farmingdale, New York. Glaxo's manager of package engineering Bruce Cohen examined the inner seals of the bottles and determined that the product had not been packaged by Glaxo. Cohen's examination, the complaint says, "revealed that said seals differed from authentic Glaxo seals with respect to the adhesion method utilized and with respect to typeface and style of the imprinted 'Glaxo' tradename logo." Therefore, Cohen found that the seals "were not authentic 'Glaxo' seals and that defendent article of drug was not packaged or distributed by Glaxo." Since Glaxo "did not authorize the use" of its name for the product, it is "a counterfeit drug" under the FD&C Act, the complaint states. World Medical had initiated a recall of various drugs including Zantac in late July because of "lack of assurance of product origin and authenticity" ("The Pink Sheet" Aug. 28, 1989, T&G-16). World Medical, which conducts business as Elm Drugs and First Providers, said that it purchased the drugs from a drug store that was going out of business.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth